Head-to-head · WeighScore
NuuVim vs Rebody Health
The verdict
NuuVim takes it — 68.2/100 to 67.7/100, but only just.
NuuVim grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound. Rebody Health is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | NuuVim | Rebody Health |
|---|---|---|
| WeighScore | 68.2/100 | 67.7/100 |
| Grade | C | C |
| Scorecard rank | #153 | #159 |
| Semaglutide | $79/mo (all doses, 3-mo plan, new patients only, compounded) | $200/mo (starting dose, compounded) |
| Tirzepatide | $133/mo (all doses, 3-mo plan, new patients only, compounded) | $250/mo (starting dose, compounded) |
| Coverage | Coverage not published | 47 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
Graded #153 · C
Strengths
- Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
- Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
- LegitScript Certified and HIPAA-compliant
- Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
- Operating legal entity disclosed: NuuVim LLC, Texas governing law
Where it loses points
- There is no month-to-month plan: every rate is billed as one three-month payment
- The advertised $79 and $133 are introductory rates for customers new to GLP-1s; on renewal they become $133 and $199.67
- The site's own llms.txt advertises pricing, FAQ and terms files that all 404
- No state count is published
- FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
Graded #159 · C
Strengths
- Publishes transparent, dose-based pricing up front on a public pricing page, so you can see costs without signing up
- Offers compounded semaglutide and tirzepatide as both weekly injections and daily oral 'melt' tablets
- Also carries brand-name Wegovy and Zepbound for patients who want FDA-approved products
- Clear plan-term vs dose-tier structure; the refill price is shown before each shipment, plus $50 off the first month
- Names its operating company (Compound Technologies Inc.) and references LegitScript approval
Where it loses points
- Individual compounding pharmacies are not named on the marketing site
- Not available in Massachusetts, Rhode Island, or Vermont
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
- Dose-scaled pricing means the monthly cost can rise as your prescribed dose increases
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.